title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,RCUS,0.046184,Neutral,-0.090173
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,RCUS,0.02074,Neutral,-0.020974
99 Biggest Movers From Yesterday,20220512T082956,https://www.benzinga.com/news/22/05/27156577/99-biggest-movers-from-yesterday,RCUS,0.063655,Neutral,-0.003576
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,RCUS,0.020404,Neutral,0.078882
Why Gilead's Cancer Biz Is Driving The Stock To A Fever Pitch,20221123T124500,https://www.investors.com/news/technology/gild-stock-surges-why-gilead-sees-its-oncology-business-as-a-force-to-be-reckoned-with/,RCUS,0.064623,Neutral,-0.09992
"Stocks That Hit 52-Week Lows On Thursday - PRA Group  ( NASDAQ:PRAA ) , Perimeter Solutions  ( NYSE:PRM ) ",20231005T172202,https://www.benzinga.com/news/23/10/35111787/stocks-that-hit-52-week-lows-on-thursday,RCUS,0.013047,Neutral,0.00439
30 Stocks Moving In Tuesday's Mid-Day Session,20220405T161259,https://www.benzinga.com/news/22/04/26480745/30-stocks-moving-in-tuesdays-mid-day-session,RCUS,0.197466,Neutral,0.004313
51 Biggest Movers From Yesterday,20220406T073509,https://www.benzinga.com/news/22/04/26492531/51-biggest-movers-from-yesterday,RCUS,0.110462,Neutral,0.010576
"Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial",20220803T141314,https://www.benzinga.com/general/biotech/22/08/28331170/biotech-daily-mercks-two-combo-cancer-trials-miss-main-goal-approval-for-sinovacs-covid-19-shot-f,RCUS,0.098659,Neutral,0.0
